The Updated Overall Survival and Genomic Analysis from a Single-Arm Phase 2 Study of Dabrafenib plus Trametinib in Patients with BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer

Planchard D, et al

American Society of Clinical Oncology 2020

The presentation that you are looking for is no longer available on this site. Please contact Novartis Oncology Medical Information at 1-844-ONC-INFO (1-844-662-4636).